Trial Profile

Clinical trial of iPSC NK-cells to treat Cancer.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Induced pluripotent stem cells-derived chimeric antigen receptor natural killer cell therapies-Cytovia Therapeutics/The New York Stem Cell Foundation (Primary)
Indications Cancer
Focus Adverse reactions
Sponsors Cytovia Therapeutics

Most Recent Events

08 Dec 2020 According to a Cytovia Therapeutics media release, the company plans to file an IND in 2021.
28 Aug 2020 New trial record
25 Aug 2020 According to a Cytovia Therapeutics media release, it plans to initiate first clinical trials with iPSC NK-cells in 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com